P
2.50
-0.06 (-2.34%)
| Previous Close | 2.56 |
| Open | 2.57 |
| Volume | 971,146 |
| Avg. Volume (3M) | 892,812 |
| Market Cap | 147,738,720 |
| Price / Book | 1.30 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2026 |
| Diluted EPS (TTM) | -1.49 |
| Total Debt/Equity (MRQ) | 2.67% |
| Current Ratio (MRQ) | 18.03 |
| Operating Cash Flow (TTM) | -40.14 M |
| Levered Free Cash Flow (TTM) | -26.32 M |
| Return on Assets (TTM) | -27.16% |
| Return on Equity (TTM) | -41.88% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Protara Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.76 |
Select this tab to load the latest available analysis.
|
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.61% |
| % Held by Institutions | 76.24% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |